ClinicalTrials.gg
RecruitingNCT07854899ECSTASIUpdated Oct 8, 2026

Natural History Study of Advanced RCD

An interventional study of Eye examinations and Questionnaire in Rod Cone Dystrophy, sponsored by SparingVision. Recruiting at 3 sites in 3 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-10-08.

Sponsored by SparingVision · Not applicable, Interventional, and Other

How we know

From the registry’s dates

  • Started Sep 2026; still recruiting 2 months later.
Updated Oct 8, 2026Now RecruitingSite recruiting status changed+1 moreGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
100
Allocation
Not applicable
Ages
18 Years and older
Sex
All
01

Study summary

ECSTASI is a Natural History Study, which will be monitoring how standard of care (SoC) affect advanced rod-cone dystrophy (RCD), a type of eye disease also known as retinitis pigmentosa. No experimental, investigational or any other drug or treatment will be tested during the study.

This study collects information in 3 parts:

Part 1: retrospective health information from medical records (up to past 10 years), Part 2: prospective health information from in-person visits (up to 1 year), and Part 3: prospective health information from medical records (up to 1 year). Participants will decide if they wish to participate in all or only to some of these parts.

02

Conditions studied

  • Rod Cone Dystrophy

Keywords

  • retinitis pigmentosa
  • standard of care (SoC)
  • Advanced RCD
  • Natural History
  • rod-cone dystrophy
03

In context

Cone-Rod Dystrophies

40 studies on the registry are indexed under Cone-Rod Dystrophies; 15 are open to participants now.

This study's planned enrollment of 100 is above the median of 28 across 28 interventional studies indexed under Cone-Rod Dystrophies.

Browse Cone-Rod Dystrophies studies →

Lead sponsor

SparingVision is the lead sponsor of 5 studies on the registry; 2 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Males and females 18 years of age or older, with history of formed vision
  2. Clinical diagnosis of advanced retinal degeneration due to RCD
  3. BCVA no better than (≥) 1.0 LogMAR (≤35 Early-Treatment Diabetic Retinopathy Study [ETDRS] letters, or 20/200 Snellen equivalent) in at least one eye
  4. Documented preservation of foveal Outer Nuclear Layer (ONL) in at least one eye

Exclusion criteria

Exclusion Criteria:

  1. Individuals who are receiving or have received an medicinal product (IMP) in another clinical trial are excluded from the prospective part . However, they can participate in the retrospective part of the study.
  2. Individuals with a medical condition (systemic or ophthalmic), psychiatric condition (including substance abuse disorder), physical examination or laboratory findings that may in the opinion of the Investigator preclude adherence to the scheduled study visits, safe participation in the study, or affect study results are excluded from participating in in-person study visits. However, they can participate in the collection of data reported during both retrospective and prospective SoC routine eye examinations.
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

05

Study design

Phase
Not applicable
Primary purpose
Other
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
100 participants (estimated)

Study arms

  • Experimental
    Prospective and/or retrospective data collection

    This Natural History study is designed as a combination of prospective and retrospective evaluations in patients diagnosed with advanced RCD. Prospective data will be collected during in-person study visits and/or SoC routine eye examinations (not planned per protocol) as they are reported in the medical records of the participant for up to 1 year after study enrollment. Retrospective data will be collected from the medical records of the participant for up to 10 years before enrollment.

    Other: Eye examinations · Other: Questionnaire

Interventions

  • OtherEye examinations

    Routine eye examinations (including slit lamp exam and dilated fundus exam), standard visual assessments (such as best corrected visual acuity test and ocular coherence tomography), evaluation of visual function (such as microperimetry).

  • OtherQuestionnaire

    Patient-reported quality of life questionnaire.

06

What researchers measure

Primary outcomes

  1. Best-corrected visual acuity (BCVA)

    Change in BCVA from Baseline to Month 6

    Time frame: At 6 months

Secondary outcomes

  1. To evaluate the effects of SoC on visual function at 1 year of follow up

    Change in BCVA from baseline to Year 1

    Time frame: At 1 year

  2. To determine the precision and reliability of the assessments of visual function measured in ECSTASI

    Test-retest variability and signal-to-noise ratio of visual function measurements such as BCVA and microperimetry.

    Time frame: 1 year

  3. To evaluate participant potential eligibility for the Phase 1/2a clinical trial of SPVN20 (NYRVANA).

    Percentage of participants potentially eligible to participate in the Phase 1/2a clinical trial of SPVN20 (NYRVANA), based on data collected in the ECSTASI study.

    Time frame: 1 year

  4. To evaluate the effects of SOC on visual function at 6 months and 1 year of follow-up for FST

    Change in FST from baseline to Month 6 and Year 1

    Time frame: 1 year

  5. To evaluate the effects of SOC on visual function at 6 months and 1 year of follow-up for microperimetry

    Change in microperimetry foveal sensitivity from baseline to Month 6 and Year 1

    Time frame: 1 year

  6. To evaluate the effects of SOC on visual function at 6 months and 1 year of follow-up for eye dominance

    Change in eye dominance from baseline to Month 6 and Year 1

    Time frame: 1 year

07

Study locations

1 of 3 sites recruiting
08

References and documents

Individual participant data

Plan to share: Undecided

No publications or documents are linked to this record.

09

Timeline

2 registry updates since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Started Sep 2026 (actual). Primary completion is estimated for Sep 2028, 24 months after the start.

How these figures are worked out, and which studies are left out of them.

Registered
Aug 17, 2026
First posted
Oct 2, 2026
StartActual
Sep 11, 2026
Primary completionEst.
Sep 2028
CompletionEst.
Sep 2028
Last update
Oct 8, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Status
Not yet recruiting→Recruiting
changed Oct 8, 2026
Sites
3 sites changed recruiting status (2 now not yet recruiting, 1 now recruiting)
Show 3 sites
  • Ghent University Hospital · Ghent, Belgiumno status→Recruiting
  • CHNO XV-XX Paris - CIC 1423 · Paris, Franceno status→Not yet recruiting
  • Royal Victoria Eye And Ear Hospital · Dublin, Irelandno status→Not yet recruiting
Oct 8, 2026
Site contacts
Changed at 1 site. See the sites
Show the site
  • Royal Victoria Eye And Ear Hospital · Dublin, IrelandContact added E•••@rveeh.ie · •••4600
Oct 8, 2026
Registered
First appeared on the registry
Oct 2, 2026
Show all 2 updates
  1. Oct 8, 2026
    Not yet recruiting→Recruiting
    3 sites changed recruiting status (2 now not yet recruiting, 1 now recruiting)
    Show 3 sites
    • Ghent University Hospital · Ghent, Belgiumno status→Recruiting
    • CHNO XV-XX Paris - CIC 1423 · Paris, Franceno status→Not yet recruiting
    • Royal Victoria Eye And Ear Hospital · Dublin, Irelandno status→Not yet recruiting
    Site contacts Changed at 1 site. See the sites
    Show the site
    • Royal Victoria Eye And Ear Hospital · Dublin, IrelandContact added E•••@rveeh.ie · •••4600
    + 2 other changes: verification date and date precision
  2. Oct 2, 2026
    First appeared on the registry

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT07854899
Lead sponsor
SparingVision
Responsible party
Sponsor
First posted
Oct 2, 2026
Start date
Sep 11, 2026
Primary completion
Sep 2028 (estimated)
Completion
Sep 2028 (estimated)
Last update
Oct 8, 2026

Study contacts

SparingVision
Contact
info@sparingvision.com
+33143462060
Medical Director
Contact

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion